Molnupiravir reduced the risk of hospitalization or death by about 50%.
Formulary Watch
Latest News
All News
Advertisement
The announcement was made by Pfizer and BioNTech on Twitter
An FDA decision is expected in late 2022.
If approved, maribavir would be the first therapy to treat transplant patients with cytomegalovirus.
Investigators found only small differences in the change in LDL-C levels in the incentive groups versus the control group
Gavreto treats patients with advanced lung care and Arcalyst treats patients with recurrent pericarditis.
Blue Plans will now have an additional home delivery option that they can choose to offer their members.
The labeling of Trikafta, which treats cystic fibrosis, has been updated to warn about the possibility of liver failure that could lead to the need for transplantation.
Talicia treats H. pylori infection, a risk factor for stomach cancer; Twirla is a hormonal contraceptive.
Advertisement
Merck plans to seek emergency use authorization for molnupiravir as the first oral treatment for COVID-19.
Three products, including Pfizer’s smoking cessation product Chantix, have been removed because generics are now available.
AstraZeneca’s long-acting antibody combination has been shown to reduce the risk of developing symptomatic infection.
Data show that the vaccine was 94% effective against moderate infection and 100% effective against severe disease.
Tecartus is the first CAR T-cell therapy approved to treat adults with relapsed or refractory ALL.
The labeling for selective serotonin reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake Inhibitors (SSNRIs) now must include information about sexual side effects in the warning and precautions and patient counseling sections.
Aetna, Cigna and UnitedHealthcare are enhancing their Medicare pharmacy benefits, including offering insulin for a copay of no more than $35 for a 30-day supply.
Given together, bamlanivimab and etesevimab have an emergency use authorization from the FDA to both treat COVID-19 and prevent infection in those who have been exposed.
Livmarli is the first drug approved for Alagille syndrome.
Effective Oct. 1, 2021, Aetna has added several cancer drugs to its formulary and has updated exclusions and nonpreferred products.
Comprehensive medication management aided by AI clinical decision support can result in a large return on investment in a high-risk population. In this study, every dollar that was invested resulted in $12 in savings or cost avoidance.
Trudhesa was approved in September to treat migraine.
The company has also launched a website for patients affected by hereditary angioedema, a rare genetic disorder.
Half of the 14 oncology indications approved in the second quarter were accelerated approvals.
This is the seventh approval for Erbitux and the only anti-EGFR antibody approved for this indication.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Tubeless AID Systems Boost HRQoL in Type 1 Diabetes
2
Current Guideline Definitions of Barrett’s Esophagus May Fall Short in Detecting Esophageal Cancers
3
Modeling Finds the Timing of Modafinil to Treat Narcolepsy Matters for Efficacy
4
Navigating Female Sexuality in Midlife Requires Provider Nuance and Patient Advocacy
5
